Opinion|Videos|April 29, 2025
Switching to Biosimilars for the Management of Psoriasis
Author(s)Aaron Farberg, MD
An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is it so critical to examine biosimilars in clinical trials?
- Discuss the importance of interchangeability and whether it is implemented in your clinical practice.
- What were the study methods for this interchangeability study?
- What were the key results seen in terms of pharmacokinetics, efficacy, and safety profile?
- How do you see the use of biosimilars evolving in the future for patients with psoriasis?
Advertisement
Related to this article
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
5 Things to Know About the One Big Beautiful Bill Act
3
New CHEST Guidelines Offer a Road Map for Bronchiectasis
4
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
5